U.S. stocks closed higher yesterday, following impressive data for a potential COVID-19 vaccine and a strong quarterly report by America’s leading investment bank, Goldman Sachs.
Recall that some hours ago, Nairametrics reported on Moderna Inc rallying after a small-scale study showed that its experimental COVID-19 vaccine produced high levels of virus-killing antibodies.
Moderna’s shares gain over 16% as COVID-19 vaccine passes first human trial
“The Moderna news woke everybody again that this is not going to last forever, and there is light at the end of the tunnel. That is why you are seeing such a strong move today into those economically sensitive stocks,” said Tim Ghriskey, Chief Investment Strategist Inverness Counsel in New York in a note Reuters.
READ ALSO: Nigerian Bourse begins Q3 2020 on a bullish note, BUACEMENT triggers rally
America’s elite bank Goldman Sachs surged after it reported that its trading revenue doubled in the second quarter, driven by high volatility in stock and bond markets since March.
In addition, Stephen Innes, Chief Global Market Strategist at AxiCorp, in a note to Nairametrics, explained geopolitical macros, affecting the U.S Stock market. He said:
“The S&P500 closed on an upbeat note as US equities continued to defy all gravity as investor optimism revels amid the progress in developing a vaccine which continues to reign supreme.
READ ALSO: U.S Stock futures soar high as investors await earning results
“Adding to the positive vibe, President Trump defused the US-China tensions and walked back an unwanted element of geopolitical risk that quite frankly no one wanted or needed at this point with COVID-19 ravaging large parts of the US consumer complex.
“The President’s backpedaling is coming at a good time and keeping the omnipresent bears and prophets of doom at bay for now.”
